4.97 score from hupso.pl for:
astrazeneca-us.com



HTML Content


Titleastrazeneca us

Length: 14, Words: 2
Description pusty

Length: 0, Words: 0
Keywords pusty
Robots index,follow
Charset UTF-8
Og Meta - Title pusty
Og Meta - Description pusty
Og Meta - Site name pusty
Tytuł powinien zawierać pomiędzy 10 a 70 znaków (ze spacjami), a mniej niż 12 słów w długości.
Meta opis powinien zawierać pomiędzy 50 a 160 znaków (łącznie ze spacjami), a mniej niż 24 słów w długości.
Kodowanie znaków powinny być określone , UTF-8 jest chyba najlepszy zestaw znaków, aby przejść z powodu UTF-8 jest bardziej międzynarodowy kodowaniem.
Otwarte obiekty wykresu powinny być obecne w stronie internetowej (więcej informacji na temat protokołu OpenGraph: http://ogp.me/)

SEO Content

Words/Characters 2737
Text/HTML 49.69 %
Headings H1 1
H2 35
H3 9
H4 1
H5 0
H6 0
H1
welcome to astrazeneca united states
H2
beginning its journey in 1953, astrazeneca became one of the first pharmaceutical companies operating in the united states
astrazeneca gives back: advancing respiratory health beyond the medicine
latest news from astrazeneca united states
astrazeneca announces subgroup analysis from falcon trial comparing faslodex® (fulvestrant) to arimidex® (anastrozole)
tagrisso® (osimertinib) demonstrates superiority over chemotherapy in egfr t790m mutation-positive non-small cell lung cancer
early data demonstrate clinical activity of acalabrutinib in difficult-to-treat chronic lymphocytic leukemia
astrazeneca announces study results show symbicort improves lung function in pediatric asthma patients
stigma, genetics and hope: 11 years with lung cancer
what does the new cancerlinq discovery initiative mean for the future of patient care?
personalized healthcare: what it means and why it matters
what getting on it means to me for american diabetes month®
how the type 2 diabetes patient community is unifying their voice online
protecting your child’s lungs this rsv season
navigating cancer clinical trials: where to start
one brave idea $75 million research award for coronary heart disease winner announced
18 years strong: living with metastatic breast cancer
new resource offers 24/7 support for those with mental illness
the power of diversity celebrated at astrazeneca’s 5th annual women’s summit
connecting the dots of hereditary cancer
making medicine personal in cancer treatments
interactive teaching model engages students in stem
making medicine personal in cardiovascular and metabolic health
mobile savings and support app offers patients new ways to manage health
patient influencers bring medical meetings to life online
harnessing the immune system to potentially revolutionize cancer treatment for patients
purposeful collaboration: teaming up to increase community impact
making medicine personal in respiratory health
asking congress to get “on it” for diabetes
“i had no idea that there were other forms of constipation” – a patient’s oic story
science of novel drug delivery in respiratory medicine
a patient’s perspective during oral, head and neck cancer awareness week
why people with type 2 diabetes should start a walking program
perspectives on cardiovascular disease: a multi-faceted condition
bringing medical meetings to everyone via social media
what science can do
H3
cookie policy
quick links

@astrazenecaus on twitter
latest az&you blog articles
global site
resources
quick links
social media
H4
H5
H6
strong
b
i
em
Bolds strong 0
b 0
i 0
em 0
Zawartość strony internetowej powinno zawierać więcej niż 250 słów, z stopa tekst / kod jest wyższy niż 20%.
Pozycji używać znaczników (h1, h2, h3, ...), aby określić temat sekcji lub ustępów na stronie, ale zwykle, użyj mniej niż 6 dla każdego tagu pozycje zachować swoją stronę zwięzły.
Styl używać silnych i kursywy znaczniki podkreślić swoje słowa kluczowe swojej stronie, ale nie nadużywać (mniej niż 16 silnych tagi i 16 znaczników kursywy)

Statystyki strony

twitter:title pusty
twitter:description pusty
google+ itemprop=name pusty
Pliki zewnętrzne 8
Pliki CSS 3
Pliki javascript 5
Plik należy zmniejszyć całkowite odwołanie plików (CSS + JavaScript) do 7-8 maksymalnie.

Linki wewnętrzne i zewnętrzne

Linki 104
Linki wewnętrzne 84
Linki zewnętrzne 20
Linki bez atrybutu Title 102
Linki z atrybutem NOFOLLOW 0
Linki - Użyj atrybutu tytuł dla każdego łącza. Nofollow link jest link, który nie pozwala wyszukiwarkom boty zrealizują są odnośniki no follow. Należy zwracać uwagę na ich użytkowania

Linki wewnętrzne

skip to content #main
skip to navigation #navigation
- - /
astrazeneca in the united states /az-in-us.html
astrazeneca in the us /az-in-us.html
contact us /az-in-us/contact-us.html
sustainability /sustainability.html
sustainability /sustainability.html
advancing patient health /sustainability/advancing-patient-health.html
improving access to care /sustainability/improving-access-to-care.html
health and science innovation /sustainability/health-and-science-innovation.html
request support /sustainability/request-support.html
astrazeneca healthcare foundation /sustainability/healthcare-foundation.html
responsible business /sustainability/responsible-business.html
corporate transparency /sustainability/corporate-transparency.html
medicines /medicines.html
astrazeneca medications /medicines/astrazeneca-medications.html
affordability /medicines/affordability.html
astrazeneca direct /medicines/astrazeneca-direct.html
product counterfeiting /medicines/product-counterfeiting.html
medical information for healthcare providers /medicines/medical-information-healthcare-providers.html
careers /careers.html
careers /careers.html
military careers /careers/military-careers.html
media /media.html
media /media.html
blog /media/astrazeneca-us-blog.html
/az-in-us.html
/sustainability.html
/medicines/astrazeneca-medications.html
/media.html
/careers.html
continue reading on our blog /media/astrazeneca-us-blog/2016/astrazeneca-gives-back-advancing-respiratory-health-beyond-the-medicine-11032016.html

astrazeneca announces subgroup analysis from falcon trial comparing faslodex® (fulvestrant) to arimidex® (anastrozole)

subset of patients with non-visceral disease may show increased sensitivity to faslodex in 1st line therapy of advanced breast cancer

astrazeneca today announced results from a pre-specified subgroup analysis of the positive phase iii falcon trial suggesting that treatment effects in terms of progression-free survival (pfs) were largely consistent across the subgroups analyzed with some possible exceptions, including patients with non-visceral disease. 

/media/press-releases/2016/astrazeneca-announces-subgroup-analysis-from-falcon-trial-comparing-faslodex-fulvestrant-to-arimidex-anastrozole-12082016.html

tagrisso® (osimertinib) demonstrates superiority over chemotherapy in egfr t790m mutation-positive non-small cell lung cancer

first randomized phase iii trial (aura3) of tagrisso against chemotherapy

tagrisso reduced risk of disease progression by 70% and improved progression-free survival (pfs) by almost six months

patients with central nervous system (cns) metastases achieved consistent results with the overall patient population in pre-specified exploratory subgroup analysis

/media/press-releases/2016/tagrisso-osimertinib-demonstrates-superiority-over-chemotherapy-in-egfr-t790m-mutation-positive-non-small-cell-lung-cancer-12062016.html

early data demonstrate clinical activity of acalabrutinib in difficult-to-treat chronic lymphocytic leukemia

phase i/ii trial findings add to growing body of data on acalabrutinib clinical profile

astrazeneca and its hematology center of excellence, acerta pharma, today announced preliminary results from the phase i/ii ace-cl-001 clinical trial of acalabrutinib in subsets of patients with two difficult-to-treat forms of chronic lymphocytic leukemia (cll), the most common type of leukemia in adults.

/media/press-releases/2016/early-data-demonstrate-clinical-activity-of-acalabrutinib-in-difficult-to-treat-chronic-lymphocytic-leukemia-12052016.html

astrazeneca announces study results show symbicort improves lung function in pediatric asthma patients

results from the international, multicenter childhood asthma safety and efficacy (chase) 3 phase iii study showed that symbicort® (budesonide/formoterol fumarate dihydrate) inhalation aerosol 80/4.5 micrograms significantly improved lung function in pediatric patients between 6 to <12 years of age with asthma versus budesonide 80 micrograms, demonstrating its appropriateness as step-up therapy in this patient population.

/media/press-releases/2016/astrazeneca-announces-study-results-show-symbicort-improves-lung-function-in-pediatric-asthma-patients-11112016.html

stigma, genetics and hope: 11 years with lung cancer

in 2005, melissa crouse was diagnosed with lung cancer and given three to five years to live. eleven years later, melissa continues to manage her disease while giving back to the lung cancer community and getting the most out of life. melissa shares her perspective on living with lung cancer, understanding the importance of biomarkers, and remaining hopeful.

/media/astrazeneca-us-blog/2016/stigma-genetics-and-hope-11-years-with-lung-cancer-12022016.html

what does the new cancerlinq discovery initiative mean for the future of patient care?

by kevin fitzpatrick, ceo, cancerlinq llc

this is an exciting time in the field of oncology—a time of rapid discovery, learning and new treatments to fight this terrible disease, as we work to provide patients with greater hope. imagine taking these daily learnings and aggregating them in one accessible place while simultaneously creating a learning platform that medical oncologists can use to help improve patient care. 

/media/astrazeneca-us-blog/2016/what-does-the-new-cancerlinq-discovery-initiative-mean-for-the-future-of-patient-care-11302016.html

personalized healthcare: what it means and why it matters

when it comes to cancer treatment, one size does not fit all. of the estimated 1.6 million americans who will be diagnosed with cancer in 2016, no two will be exactly the same. more and more, we’re hearing (and using) buzzwords to this effect: personalized healthcare. precision medicine. targeted therapy

/media/astrazeneca-us-blog/2016/personalized-healthcare-what-it-means-and-why-it-matters-11282016.html

what getting on it means to me for american diabetes month®

by dr. phil mcgraw

as someone who has lived with type 2 diabetes for more than 25 years, i understand the day-to-day issues that accompany managing a lifelong disease. it’s important to me to amplify the conversation around these challenges that people living with type 2 diabetes experience. 

/media/astrazeneca-us-blog/2016/what-getting-on-it-means-to-me-for-american-diabetes-month-11162016.html

how the type 2 diabetes patient community is unifying their voice online

while online conversations about diabetes are on the rise and people with diabetes have cultivated the diabetes online community (#doc) as a way to connect with one another, those living with type 2 diabetes seem to play a less active part in the dialogue. to help strengthen and elevate the voices of type 2 diabetes advocates, astrazeneca recently hosted members of the type 2 community for diabeteslinkup: in it 2gether.

/media/astrazeneca-us-blog/2016/how-the-type-2-diabetes-patient-community-is-unifying-their-voice-online-11112016.html

protecting your child’s lungs this rsv season

as seasonal viruses begin to circulate this autumn, there is no better time to educate new and expecting parents of a common virus contracted by nearly 100 percent of infants by the age of two – respiratory syncytial virus (rsv). rsv disease is the leading cause of hospitalization for babies in the us during their first year of life, and can cause up to approximately 200 infant deaths in the us each year.

/media/astrazeneca-us-blog/2016/protecting-your-childs-lungs-this-rsv-season-10312016.html

navigating cancer clinical trials: where to start

when patients are diagnosed with cancer, the following questions may be top of mind as they begin their treatment journey: should i consider joining a clinical trial? what does clinical trial participation entail? how can i locate the most appropriate clinical trial for my particular disease? how do i actually enroll in a clinical trial? 

/media/astrazeneca-us-blog/2016/navigating-cancer-clinical-trials-where-to-start-10182016.html

one brave idea $75 million research award for coronary heart disease winner announced

astrazeneca, the american heart association (aha) and verily (formerly google life sciences) announced wednesday that dr. calum macrae is the recipient of a $75 million research award to study coronary heart disease (chd) and its consequences. 

/media/astrazeneca-us-blog/2016/one-brave-idea-75-million-research-award-for-coronary-heart-disease-winner-announced-10052016.html

18 years strong: living with metastatic breast cancer

when doctors diagnosed kristin johnson st. goddard with metastatic breast cancer, she was given 18 months to live. fast forward 18 years and different treatment regimens - kristin is still going strong. while some days are challenging, she continues to lead a good life, and remains hopeful that one day, there will be a cure. see her story. 

/media/astrazeneca-us-blog/2016/18-years-strong-living-with-metastatic-breast-cancer-10032016.html

new resource offers 24/7 support for those with mental illness

nine years ago, danei edelen was established in her career as a marketing executive and happily raising a family with her husband in ohio. then something unexpected happened. “after five nights of no sleep, hallucinations, i sought hospitalization,” danei said. she subsequently learned she had experienced a psychotic break caused by an underlying and undiagnosed mental illness called bipolar disorder. 

/media/astrazeneca-us-blog/2016/new-resource-offers-24-7-support-for-those-with-mental-illness-092620161.html

the power of diversity celebrated at astrazeneca’s 5th annual women’s summit

“leadership is surrounding yourself with others who do not think like you and bringing out the best in those people.”

“fostering diversity does not need justification; it is simply the right thing to do.”

“diversity fuels innovation; a team needs individuals who approach challenges differently.”  

these messages were among those heard by hundreds of our employees last month at the 5th annual women’s summit held on our gaithersburg campus. 

/media/astrazeneca-us-blog/2016/power-of-diversity-celebrated-at-astrazenecas-5th-annual-womens-summit-09212016.html

connecting the dots of hereditary cancer

by sue friedman, dvm, founder and executive director, facing our risk of cancer empowered (force)

in 1996, at the age of 33, i was diagnosed with breast cancer. my diagnosis came out of the blue. i was otherwise healthy, and only one relative, my grandmother, in my small family tree had also had cancer. my doctors didn’t appreciate how significant that one relative could be, and my health care team didn’t mention genetic testing. i had no idea that my cancer could be hereditary.

/media/astrazeneca-us-blog/2016/connecting-the-dots-of-hereditary-cancer-1092016.html

making medicine personal in cancer treatments

cancer is one of mankind’s greatest scientific and health challenges. today, nearly 14.5 million americans[1] have cancer and the total annual cost of their treatment is estimated at $125 billion[2]. with astonishing numbers like these, it’s more important than ever before that patients receive the best care possible while effectively managing overall costs to the healthcare system.

/media/astrazeneca-us-blog/2016/making-medicine-personal-in-cancer-treatments.html

interactive teaching model engages students in stem

not long ago, emma waldman was a fifth grader just outside of boston, massachusetts, disengaged from her classes in science and math. “[they] were always hard to conceptualize, i never really saw them as practical or important,” says emma.  she is certainly not alone; 83% of students in the united states are not proficient or not interested in science, technology, engineering and math (stem) fields by eighth grade.

/media/astrazeneca-us-blog/2016/interactive-teaching-model-engages-students-in-stem-27062016.html

making medicine personal in cardiovascular and metabolic health

cardiovascular and metabolic diseases are complex and require life-long attention. patients need to address many factors — from preventive measures, to care at the onset of disease to ongoing disease management. our goal at astrazeneca is to reduce the high cost of long-term complications with comprehensive support programs and resources that provide a thoughtful, personalized approach. we do this to help patients adhere to their treatment, reduce re-admission rates and change the course of disease by improving quality of care and ensuring that innovative medicines are being researched and accessible to patients in a timely manner.

/media/astrazeneca-us-blog/2016/making-medicine-personal-in-cardiovascular-and-metabolic-health-210620161.html

mobile savings and support app offers patients new ways to manage health

when managing your health, convenience is key. we all want tools that enable us to lead healthier lives while saving us time and money. that’s why astrazeneca is introducing an industry leading digital support program called azhelps, built to help you better manage your astrazeneca medications and your health.

/media/astrazeneca-us-blog/2016/mobile-savings-and-support-app-offers-patients-new-ways-to-manage-health-14062016.html

patient influencers bring medical meetings to life online

we recently took a look at how social media has transformed medical meetings, enabling attendees to engage and connect in real time, but also allowing anyone with internet access to join the conversation from wherever they are. as we approach the american diabetes association’s 76th scientific sessions taking place june 10-14, those at the meeting will take to social media to share their #2016ada experience with the world, from new research presented to exploring new orleans and everything in between.

/media/astrazeneca-us-blog/2016/patient-influencers-bring-medical-meetings-to-life-online-08062016.html

harnessing the immune system to potentially revolutionize cancer treatment for patients

this year alone, nearly 1.7 million new cancer cases are expected to be diagnosed in the united states. a patient newly diagnosed with cancer, after absorbing the unwanted news from his or her physician, will want to know, “what treatments will i need? where do i begin?”

/media/astrazeneca-us-blog/2016/harnessing-the-immune-system-to-potentially-revolutionize-cancer-treatment-for-patients-06012016.html

purposeful collaboration: teaming up to increase community impact

astrazeneca recently hosted a number of non-profit partners at our north america headquarters in wilmington, delaware for an event, entitled purposeful collaboration, which was developed based on their interest in collaborating across organizational lines for greater impact.

/media/astrazeneca-us-blog/2016/purposeful-collaboration-teaming-up-to-increase-community-impact24052016.html

making medicine personal in respiratory health

your health and that of your loved ones is one of the most important aspects of life. it’s also the most important aspect of our work. for more than 40 years, we’ve addressed respiratory challenges to improve millions of lives – and we’re not slowing down. 

/media/astrazeneca-us-blog/2016/making-medicine-personal-in-respiratory-health-05132016.html

asking congress to get “on it” for diabetes

by topher brooke, vice president, u.s. diabetes, astrazeneca

on may 11, astrazeneca and dr. phil will join policymakers and advocates on capitol hill to ask congress for more support of those living with and at risk for developing diabetes and call attention to the patient experience. 

/media/astrazeneca-us-blog/2016/asking-congress-to-get-on-it-for-diabetes-05042016.html

“i had no idea that there were other forms of constipation” – a patient’s oic story

for patients with chronic pain, taking a prescribed opioid treatment for long-term pain management may provide pain relief but can also cause opioid-induced constipation (oic). however, some patients may not realize that constipation is one of the most common side effects of their prescription opioid treatment. 

/media/astrazeneca-us-blog/2016/i-had-no-idea-that-there-were-other-forms-of-constipation-a-patients-oic-story-05022016.html

science of novel drug delivery in respiratory medicine

what exactly is co-suspension technology? in our recent blog post, find facts about co-suspension technology to answer this question.

/media/astrazeneca-us-blog/2016/science-of-novel-drug-delivery-in-respiratory-medicine-04262016.html

a patient’s perspective during oral, head and neck cancer awareness week

by jessica tar, patient advocate

2010 was truly a year that delivered the worst to my life. in april, the unexpected death of my father, a non-smoker, from lung cancer, revealed the mystery of this disease and at times, its unidentifiable origins. my shock was to be exceeded just nine months after my father’s death when i received the news of my own diagnosis of squamous cell carcinoma.

/media/astrazeneca-us-blog/2016/a-patients-perspective-during-oral-head-and-neck-cancer-awareness-04152016.html

why people with type 2 diabetes should start a walking program

today, more than 145 million adults in the united states include walking as part of a physically active lifestyle, and this staple exercise continues to grow in popularity. after all, walking can be done just about anywhere and, for most, is as simple as putting one foot in front of the other.

/media/astrazeneca-us-blog/2016/why-people-with-type-2-diabetes-should-start-a-walking-program-04052016.html

perspectives on cardiovascular disease: a multi-faceted condition

by steven zelenkofske, do, vice president, us medical affairs, cardiovascular, astrazeneca

with acc coming up this weekend, i caught up with roxana mehran, md, of mount sinai school of medicine to discuss the multi-faceted nature of cardiovascular disease (cvd) and how research and science is helping to evolve the way we view the causes and management of cvd.

/media/astrazeneca-us-blog/2016/perspectives-on-cardiovascular-disease-a-multi-faceted-03312016.html

bringing medical meetings to everyone via social media

social media takes medical meetings beyond the convention center walls to provide a real-time yet enduring story of patient experiences, scientific breakthroughs and inspirational speakers. it opens the meetings up to anyone, whether they have a deep or passing interest in all or any of the subjects being discussed, while democratizing the sharing of information.

/media/astrazeneca-us-blog/2016/bringing-medical-meetings-to-everyone-via-social-media-05022016.html
astrazeneca in the us /az-in-us.html
community support /sustainability/request-support.html
affordability /medicines/affordability.html
az&you blog /media/astrazeneca-us-blog.html
contact us /az-in-us/contact-us.html
media /media.html
careers /careers.html
medicines /medicines/astrazeneca-medications.html
privacy notice /privacy-notice.html
legal notice /legal-notice.html
california supply chains disclosure /california-supply-chains-disclosure.html
sitemap /sitemap.html
copyright /copyright.html
cancel #
continue #
? #!
i disagree #
i agree #
? #!
? #!

Linki zewnętrzne

cookie notice. http://www.astrazeneca.com/cookies.html
az network https://www.astrazeneca.com/global/en/aznetwork.html
global site https://www.astrazeneca.com
- https://www.twitter.com/astrazenecaus
reply https://twitter.com/intent/tweet?in_reply_to=806975502904868864
retweet 16 https://twitter.com/intent/retweet?tweet_id=806975502904868864
favorite 0 https://twitter.com/intent/favorite?tweet_id=806975502904868864
- https://www.twitter.com/astrazenecaus
reply https://twitter.com/intent/tweet?in_reply_to=806921794863190016
retweet 0 https://twitter.com/intent/retweet?tweet_id=806921794863190016
favorite 2 https://twitter.com/intent/favorite?tweet_id=806921794863190016
- https://www.twitter.com/astrazenecaus
reply https://twitter.com/intent/tweet?in_reply_to=806906693057712128
retweet 0 https://twitter.com/intent/retweet?tweet_id=806906693057712128
favorite 0 https://twitter.com/intent/favorite?tweet_id=806906693057712128
follow astrazenecaus https://twitter.com/astrazenecaus
explore more on on our global site https://www.astrazeneca.com/what-science-can-do.html
global site https://www.astrazeneca.com/
twitter https://twitter.com/astrazenecaus
facebook https://www.facebook.com/astrazenecauscommunityconnections/

Zdjęcia

Zdjęcia 41
Zdjęcia bez atrybutu ALT 35
Zdjęcia bez atrybutu TITLE 41
Korzystanie Obraz ALT i TITLE atrybutu dla każdego obrazu.

Zdjęcia bez atrybutu TITLE

/etc/designs/az/img/logo-az-condensed.png
/etc/designs/az/img/logo-az-condensed-white.png
/etc/designs/az/img/logo-az.png
/etc/designs/az/img/logo-az-white.png
/content/dam/az/science at az/biologics.jpg/_jcr_content/renditions/cq5dam.web.1200.biologics.jpg
/content/dam/az-us/icons/usa icon.png/_jcr_content/renditions/cq5dam.web.100.square.usa icon.png
/content/dam/az-us/icons/people.png/_jcr_content/renditions/cq5dam.web.100.square.people.png
/content/dam/az-us/icons/meds.png/_jcr_content/renditions/cq5dam.web.100.square.meds.png
/content/dam/az-us/icons/media2.png/_jcr_content/renditions/cq5dam.web.100.square.media2.png
/content/dam/az-us/icons/careers.png/_jcr_content/renditions/cq5dam.web.100.square.careers.png
/content/dam/az-us/blog assets/edna.jpg/_jcr_content/renditions/cq5dam.web.620.edna.jpg
https://pbs.twimg.com/profile_images/1488204784/az_symbol_rgb_normal.jpg
https://pbs.twimg.com/profile_images/1488204784/az_symbol_rgb_normal.jpg
https://pbs.twimg.com/profile_images/1488204784/az_symbol_rgb_normal.jpg
/content/dam/az-us/blog assets/melissa crouse headshot2.jpg/_jcr_content/renditions/cq5dam.web.320.melissa crouse headshot2.jpg
/content/dam/az-us/blog assets/asc_141443 cancerlinq logo update-cmyk.jpg/_jcr_content/renditions/cq5dam.web.320.asc_141443 cancerlinq logo update-cmyk.jpg
/content/dam/az-us/blog assets/phc blogpost_11-14-16.jpg/_jcr_content/renditions/cq5dam.web.320.phc blogpost_11-14-16.jpg
/content/dam/az-us/blog assets/dr. phil jpg-c2.jpg/_jcr_content/renditions/cq5dam.web.320.dr. phil jpg-c2.jpg
/content/dam/az-us/blog assets/img_4102.jpg/_jcr_content/renditions/cq5dam.web.320.img_4102.jpg
/content/dam/az-us/blog assets/judsonfamily709_650px4.jpg/_jcr_content/renditions/cq5dam.web.320.judsonfamily709_650px4.jpg
/content/dam/az-us/blog assets/csl_logo_3color_horiz.jpg/_jcr_content/renditions/cq5dam.web.320.csl_logo_3color_horiz.jpg
/content/dam/az-us/blog assets/dsc_6029.jpg/_jcr_content/renditions/cq5dam.web.320.dsc_6029.jpg
/content/dam/az-us/blog assets/img_20151106_183406274.jpg/_jcr_content/renditions/cq5dam.web.320.img_20151106_183406274.jpg
/content/dam/az-us/blog assets/na_3b.jpg/_jcr_content/renditions/cq5dam.web.320.na_3b.jpg
/content/dam/az-us/blog assets/bahija panel.jpg/_jcr_content/renditions/cq5dam.web.320.bahija panel.jpg
/content/dam/az-us/blog assets/sue friedman_photo 4.jpg/_jcr_content/renditions/cq5dam.web.320.sue friedman_photo 4.jpg
/content/dam/az-us/blog assets/az1467_screen.jpg/_jcr_content/renditions/cq5dam.web.320.az1467_screen.jpg
/content/dam/az-us/media/blogs/2016/stem blog_header.jpg/_jcr_content/renditions/cq5dam.web.320.stem blog_header.jpg
/content/dam/az-us/media/blogs/2016/az1427_screen.jpg/_jcr_content/renditions/cq5dam.web.320.az1427_screen.jpg
/content/dam/az-us/media/blogs/2016/blog.jpg/_jcr_content/renditions/cq5dam.web.320.blog.jpg
/content/dam/az-us/media/blogs/2016/scottjohnson_headshot.jpg/_jcr_content/renditions/cq5dam.web.320.scottjohnson_headshot.jpg
/content/dam/az-us/blog assets/healthconnectionsblog01_v1 (2).jpg/_jcr_content/renditions/cq5dam.web.320.healthconnectionsblog01_v1 (2).jpg
/content/dam/az-us/media/blogs/2016/in-vivo-blog-pic.jpg/_jcr_content/renditions/cq5dam.web.320.in-vivo-blog-pic.jpg
/content/dam/az-us/blog assets/az1497_screen2.jpg/_jcr_content/renditions/cq5dam.web.320.az1497_screen2.jpg
/content/dam/az-us/topher brooke headshot-272x179.jpg/_jcr_content/renditions/cq5dam.web.320.topher brooke headshot-272x179.jpg
/content/dam/az-us/lynn.jpg/_jcr_content/renditions/cq5dam.web.320.lynn.jpg
/content/dam/az-us/blog assets/cst_video_1000.png/_jcr_content/renditions/cq5dam.web.320.cst_video_1000.png
/content/dam/az-us/blog assets/christening photo5.jpg/_jcr_content/renditions/cq5dam.web.320.christening photo5.jpg
/content/dam/az-us/blog assets/az blog header image2.jpg/_jcr_content/renditions/cq5dam.web.320.az blog header image2.jpg
/content/dam/az-us/blog assets/az1588_cardiac_regenerating_muscle_cells_screen.jpg/_jcr_content/renditions/cq5dam.web.320.az1588_cardiac_regenerating_muscle_cells_screen.jpg
/content/dam/az-us/shutterstock_174838673.jpg/_jcr_content/renditions/cq5dam.web.320.shutterstock_174838673.jpg

Zdjęcia bez atrybutu ALT

/content/dam/az-us/icons/usa icon.png/_jcr_content/renditions/cq5dam.web.100.square.usa icon.png
/content/dam/az-us/icons/people.png/_jcr_content/renditions/cq5dam.web.100.square.people.png
/content/dam/az-us/icons/meds.png/_jcr_content/renditions/cq5dam.web.100.square.meds.png
/content/dam/az-us/icons/media2.png/_jcr_content/renditions/cq5dam.web.100.square.media2.png
/content/dam/az-us/icons/careers.png/_jcr_content/renditions/cq5dam.web.100.square.careers.png
https://pbs.twimg.com/profile_images/1488204784/az_symbol_rgb_normal.jpg
https://pbs.twimg.com/profile_images/1488204784/az_symbol_rgb_normal.jpg
https://pbs.twimg.com/profile_images/1488204784/az_symbol_rgb_normal.jpg
/content/dam/az-us/blog assets/melissa crouse headshot2.jpg/_jcr_content/renditions/cq5dam.web.320.melissa crouse headshot2.jpg
/content/dam/az-us/blog assets/asc_141443 cancerlinq logo update-cmyk.jpg/_jcr_content/renditions/cq5dam.web.320.asc_141443 cancerlinq logo update-cmyk.jpg
/content/dam/az-us/blog assets/phc blogpost_11-14-16.jpg/_jcr_content/renditions/cq5dam.web.320.phc blogpost_11-14-16.jpg
/content/dam/az-us/blog assets/dr. phil jpg-c2.jpg/_jcr_content/renditions/cq5dam.web.320.dr. phil jpg-c2.jpg
/content/dam/az-us/blog assets/img_4102.jpg/_jcr_content/renditions/cq5dam.web.320.img_4102.jpg
/content/dam/az-us/blog assets/judsonfamily709_650px4.jpg/_jcr_content/renditions/cq5dam.web.320.judsonfamily709_650px4.jpg
/content/dam/az-us/blog assets/csl_logo_3color_horiz.jpg/_jcr_content/renditions/cq5dam.web.320.csl_logo_3color_horiz.jpg
/content/dam/az-us/blog assets/dsc_6029.jpg/_jcr_content/renditions/cq5dam.web.320.dsc_6029.jpg
/content/dam/az-us/blog assets/img_20151106_183406274.jpg/_jcr_content/renditions/cq5dam.web.320.img_20151106_183406274.jpg
/content/dam/az-us/blog assets/na_3b.jpg/_jcr_content/renditions/cq5dam.web.320.na_3b.jpg
/content/dam/az-us/blog assets/bahija panel.jpg/_jcr_content/renditions/cq5dam.web.320.bahija panel.jpg
/content/dam/az-us/blog assets/sue friedman_photo 4.jpg/_jcr_content/renditions/cq5dam.web.320.sue friedman_photo 4.jpg
/content/dam/az-us/blog assets/az1467_screen.jpg/_jcr_content/renditions/cq5dam.web.320.az1467_screen.jpg
/content/dam/az-us/media/blogs/2016/stem blog_header.jpg/_jcr_content/renditions/cq5dam.web.320.stem blog_header.jpg
/content/dam/az-us/media/blogs/2016/az1427_screen.jpg/_jcr_content/renditions/cq5dam.web.320.az1427_screen.jpg
/content/dam/az-us/media/blogs/2016/blog.jpg/_jcr_content/renditions/cq5dam.web.320.blog.jpg
/content/dam/az-us/media/blogs/2016/scottjohnson_headshot.jpg/_jcr_content/renditions/cq5dam.web.320.scottjohnson_headshot.jpg
/content/dam/az-us/blog assets/healthconnectionsblog01_v1 (2).jpg/_jcr_content/renditions/cq5dam.web.320.healthconnectionsblog01_v1 (2).jpg
/content/dam/az-us/media/blogs/2016/in-vivo-blog-pic.jpg/_jcr_content/renditions/cq5dam.web.320.in-vivo-blog-pic.jpg
/content/dam/az-us/blog assets/az1497_screen2.jpg/_jcr_content/renditions/cq5dam.web.320.az1497_screen2.jpg
/content/dam/az-us/topher brooke headshot-272x179.jpg/_jcr_content/renditions/cq5dam.web.320.topher brooke headshot-272x179.jpg
/content/dam/az-us/lynn.jpg/_jcr_content/renditions/cq5dam.web.320.lynn.jpg
/content/dam/az-us/blog assets/cst_video_1000.png/_jcr_content/renditions/cq5dam.web.320.cst_video_1000.png
/content/dam/az-us/blog assets/christening photo5.jpg/_jcr_content/renditions/cq5dam.web.320.christening photo5.jpg
/content/dam/az-us/blog assets/az blog header image2.jpg/_jcr_content/renditions/cq5dam.web.320.az blog header image2.jpg
/content/dam/az-us/blog assets/az1588_cardiac_regenerating_muscle_cells_screen.jpg/_jcr_content/renditions/cq5dam.web.320.az1588_cardiac_regenerating_muscle_cells_screen.jpg
/content/dam/az-us/shutterstock_174838673.jpg/_jcr_content/renditions/cq5dam.web.320.shutterstock_174838673.jpg

Ranking:


Alexa Traffic
Daily Global Rank Trend
Daily Reach (Percent)









Majestic SEO











Text on page:

skip to content skip to navigation cookie policy this website uses cookies to help us give you the best experience when you visit. by using this website you consent to our use of these cookies. find out more about how we use cookies and how to manage them by reading our cookie notice. close search menu search search search close astrazeneca in the united states astrazeneca in the us contact us sustainability sustainability advancing patient health improving access to care health and science innovation request support astrazeneca healthcare foundation responsible business corporate transparency medicines astrazeneca medications affordability astrazeneca direct product counterfeiting medical information for healthcare providers careers careers military careers media media blog more hide az network global site welcome to astrazeneca united states beginning its journey in 1953, astrazeneca became one of the first pharmaceutical companies operating in the united states quick links astrazeneca in us sustainability medicines media careers astrazeneca gives back: advancing respiratory health beyond the medicine “before being diagnosed with copd, i lived a dramatically wonderful life. as my disease has progressed, it’s become harder for me to do the things i never thought twice about,” shares edna shattuck, a chronic obstructive pulmonary disease (copd) patient and retired nurse in chevy chase, md. edna is one of more than 15 million americans diagnosed with copd, the third leading cause of death in the united states and the second leading cause of disability. continue reading on our blog latest news from astrazeneca united states astrazeneca announces subgroup analysis from falcon trial comparing faslodex® (fulvestrant) to arimidex® (anastrozole) subset of patients with non-visceral disease may show increased sensitivity to faslodex in 1st line therapy of advanced breast cancer astrazeneca today announced results from a pre-specified subgroup analysis of the positive phase iii falcon trial suggesting that treatment effects in terms of progression-free survival (pfs) were largely consistent across the subgroups analyzed with some possible exceptions, including patients with non-visceral disease. 8 december 2016 tagrisso® (osimertinib) demonstrates superiority over chemotherapy in egfr t790m mutation-positive non-small cell lung cancer first randomized phase iii trial (aura3) of tagrisso against chemotherapy tagrisso reduced risk of disease progression by 70% and improved progression-free survival (pfs) by almost six months patients with central nervous system (cns) metastases achieved consistent results with the overall patient population in pre-specified exploratory subgroup analysis 6 december 2016 @astrazenecaus on twitter astrazenecaus @astrazenecaus rt @repcardenas: proud that congress got together when it was important to pass #gamechanger 21st century cures act. #curesnow https://t.c… reply retweet 16 favorite 0 dec 08 astrazenecaus @astrazenecaus despite living with mbc for almost 3 years, christine shares her message of being in the present #sabcs16 https://t.co/2ulaob27nr reply retweet 0 favorite 2 dec 08 astrazenecaus @astrazenecaus we’re at #sabcs16 to share how we’re advancing #metastatic #breastcancer research. we look forward to connecting wi… https://t.co/ufib53mv3q reply retweet 0 favorite 0 dec 08 follow astrazenecaus early data demonstrate clinical activity of acalabrutinib in difficult-to-treat chronic lymphocytic leukemia phase i/ii trial findings add to growing body of data on acalabrutinib clinical profile astrazeneca and its hematology center of excellence, acerta pharma, today announced preliminary results from the phase i/ii ace-cl-001 clinical trial of acalabrutinib in subsets of patients with two difficult-to-treat forms of chronic lymphocytic leukemia (cll), the most common type of leukemia in adults. 5 december 2016 astrazeneca announces study results show symbicort improves lung function in pediatric asthma patients results from the international, multicenter childhood asthma safety and efficacy (chase) 3 phase iii study showed that symbicort® (budesonide/formoterol fumarate dihydrate) inhalation aerosol 80/4.5 micrograms significantly improved lung function in pediatric patients between 6 to <12 years of age with asthma versus budesonide 80 micrograms, demonstrating its appropriateness as step-up therapy in this patient population. 11 november 2016 latest az&you blog articles stigma, genetics and hope: 11 years with lung cancer in 2005, melissa crouse was diagnosed with lung cancer and given three to five years to live. eleven years later, melissa continues to manage her disease while giving back to the lung cancer community and getting the most out of life. melissa shares her perspective on living with lung cancer, understanding the importance of biomarkers, and remaining hopeful. 2 december 2016 what does the new cancerlinq discovery initiative mean for the future of patient care? by kevin fitzpatrick, ceo, cancerlinq llc this is an exciting time in the field of oncology—a time of rapid discovery, learning and new treatments to fight this terrible disease, as we work to provide patients with greater hope. imagine taking these daily learnings and aggregating them in one accessible place while simultaneously creating a learning platform that medical oncologists can use to help improve patient care. 30 november 2016 personalized healthcare: what it means and why it matters when it comes to cancer treatment, one size does not fit all. of the estimated 1.6 million americans who will be diagnosed with cancer in 2016, no two will be exactly the same. more and more, we’re hearing (and using) buzzwords to this effect: personalized healthcare. precision medicine. targeted therapy. 28 november 2016 what getting on it means to me for american diabetes month® by dr. phil mcgraw as someone who has lived with type 2 diabetes for more than 25 years, i understand the day-to-day issues that accompany managing a lifelong disease. it’s important to me to amplify the conversation around these challenges that people living with type 2 diabetes experience. 16 november 2016 how the type 2 diabetes patient community is unifying their voice online while online conversations about diabetes are on the rise and people with diabetes have cultivated the diabetes online community (#doc) as a way to connect with one another, those living with type 2 diabetes seem to play a less active part in the dialogue. to help strengthen and elevate the voices of type 2 diabetes advocates, astrazeneca recently hosted members of the type 2 community for diabeteslinkup: in it 2gether. 11 november 2016 protecting your child’s lungs this rsv season as seasonal viruses begin to circulate this autumn, there is no better time to educate new and expecting parents of a common virus contracted by nearly 100 percent of infants by the age of two – respiratory syncytial virus (rsv). rsv disease is the leading cause of hospitalization for babies in the us during their first year of life, and can cause up to approximately 200 infant deaths in the us each year. 31 october 2016 navigating cancer clinical trials: where to start when patients are diagnosed with cancer, the following questions may be top of mind as they begin their treatment journey: should i consider joining a clinical trial? what does clinical trial participation entail? how can i locate the most appropriate clinical trial for my particular disease? how do i actually enroll in a clinical trial? 18 october 2016 one brave idea $75 million research award for coronary heart disease winner announced astrazeneca, the american heart association (aha) and verily (formerly google life sciences) announced wednesday that dr. calum macrae is the recipient of a $75 million research award to study coronary heart disease (chd) and its consequences. 5 october 2016 18 years strong: living with metastatic breast cancer when doctors diagnosed kristin johnson st. goddard with metastatic breast cancer, she was given 18 months to live. fast forward 18 years and different treatment regimens - kristin is still going strong. while some days are challenging, she continues to lead a good life, and remains hopeful that one day, there will be a cure. see her story. 3 october 2016 new resource offers 24/7 support for those with mental illness nine years ago, danei edelen was established in her career as a marketing executive and happily raising a family with her husband in ohio. then something unexpected happened. “after five nights of no sleep, hallucinations, i sought hospitalization,” danei said. she subsequently learned she had experienced a psychotic break caused by an underlying and undiagnosed mental illness called bipolar disorder. 26 september 2016 the power of diversity celebrated at astrazeneca’s 5th annual women’s summit “leadership is surrounding yourself with others who do not think like you and bringing out the best in those people.” “fostering diversity does not need justification; it is simply the right thing to do.” “diversity fuels innovation; a team needs individuals who approach challenges differently.” these messages were among those heard by hundreds of our employees last month at the 5th annual women’s summit held on our gaithersburg campus. 21 september 2016 connecting the dots of hereditary cancer by sue friedman, dvm, founder and executive director, facing our risk of cancer empowered (force) in 1996, at the age of 33, i was diagnosed with breast cancer. my diagnosis came out of the blue. i was otherwise healthy, and only one relative, my grandmother, in my small family tree had also had cancer. my doctors didn’t appreciate how significant that one relative could be, and my health care team didn’t mention genetic testing. i had no idea that my cancer could be hereditary. 1 september 2016 making medicine personal in cancer treatments cancer is one of mankind’s greatest scientific and health challenges. today, nearly 14.5 million americans[1] have cancer and the total annual cost of their treatment is estimated at $125 billion[2]. with astonishing numbers like these, it’s more important than ever before that patients receive the best care possible while effectively managing overall costs to the healthcare system. 21 july 2016 interactive teaching model engages students in stem not long ago, emma waldman was a fifth grader just outside of boston, massachusetts, disengaged from her classes in science and math. “[they] were always hard to conceptualize, i never really saw them as practical or important,” says emma. she is certainly not alone; 83% of students in the united states are not proficient or not interested in science, technology, engineering and math (stem) fields by eighth grade. 27 june 2016 making medicine personal in cardiovascular and metabolic health cardiovascular and metabolic diseases are complex and require life-long attention. patients need to address many factors — from preventive measures, to care at the onset of disease to ongoing disease management. our goal at astrazeneca is to reduce the high cost of long-term complications with comprehensive support programs and resources that provide a thoughtful, personalized approach. we do this to help patients adhere to their treatment, reduce re-admission rates and change the course of disease by improving quality of care and ensuring that innovative medicines are being researched and accessible to patients in a timely manner. 21 june 2016 mobile savings and support app offers patients new ways to manage health when managing your health, convenience is key. we all want tools that enable us to lead healthier lives while saving us time and money. that’s why astrazeneca is introducing an industry leading digital support program called azhelps, built to help you better manage your astrazeneca medications and your health. 14 june 2016 patient influencers bring medical meetings to life online we recently took a look at how social media has transformed medical meetings, enabling attendees to engage and connect in real time, but also allowing anyone with internet access to join the conversation from wherever they are. as we approach the american diabetes association’s 76th scientific sessions taking place june 10-14, those at the meeting will take to social media to share their #2016ada experience with the world, from new research presented to exploring new orleans and everything in between. 8 june 2016 harnessing the immune system to potentially revolutionize cancer treatment for patients this year alone, nearly 1.7 million new cancer cases are expected to be diagnosed in the united states. a patient newly diagnosed with cancer, after absorbing the unwanted news from his or her physician, will want to know, “what treatments will i need? where do i begin?” 1 june 2016 purposeful collaboration: teaming up to increase community impact astrazeneca recently hosted a number of non-profit partners at our north america headquarters in wilmington, delaware for an event, entitled purposeful collaboration, which was developed based on their interest in collaborating across organizational lines for greater impact. 18 may 2016 making medicine personal in respiratory health your health and that of your loved ones is one of the most important aspects of life. it’s also the most important aspect of our work. for more than 40 years, we’ve addressed respiratory challenges to improve millions of lives – and we’re not slowing down. 13 may 2016 asking congress to get “on it” for diabetes by topher brooke, vice president, u.s. diabetes, astrazeneca on may 11, astrazeneca and dr. phil will join policymakers and advocates on capitol hill to ask congress for more support of those living with and at risk for developing diabetes and call attention to the patient experience. 4 may 2016 “i had no idea that there were other forms of constipation” – a patient’s oic story for patients with chronic pain, taking a prescribed opioid treatment for long-term pain management may provide pain relief but can also cause opioid-induced constipation (oic). however, some patients may not realize that constipation is one of the most common side effects of their prescription opioid treatment. 2 may 2016 science of novel drug delivery in respiratory medicine what exactly is co-suspension technology? in our recent blog post, find facts about co-suspension technology to answer this question. 26 april 2016 a patient’s perspective during oral, head and neck cancer awareness week by jessica tar, patient advocate 2010 was truly a year that delivered the worst to my life. in april, the unexpected death of my father, a non-smoker, from lung cancer, revealed the mystery of this disease and at times, its unidentifiable origins. my shock was to be exceeded just nine months after my father’s death when i received the news of my own diagnosis of squamous cell carcinoma. 15 april 2016 why people with type 2 diabetes should start a walking program today, more than 145 million adults in the united states include walking as part of a physically active lifestyle, and this staple exercise continues to grow in popularity. after all, walking can be done just about anywhere and, for most, is as simple as putting one foot in front of the other. 5 april 2016 perspectives on cardiovascular disease: a multi-faceted condition by steven zelenkofske, do, vice president, us medical affairs, cardiovascular, astrazeneca with acc coming up this weekend, i caught up with roxana mehran, md, of mount sinai school of medicine to discuss the multi-faceted nature of cardiovascular disease (cvd) and how research and science is helping to evolve the way we view the causes and management of cvd. 31 march 2016 bringing medical meetings to everyone via social media social media takes medical meetings beyond the convention center walls to provide a real-time yet enduring story of patient experiences, scientific breakthroughs and inspirational speakers. it opens the meetings up to anyone, whether they have a deep or passing interest in all or any of the subjects being discussed, while democratizing the sharing of information. 23 march 2016 load more blog posts what science can do if you are passionate about science, these stories will show you how the latest and most exciting projects we have been working on and the people behind them. explore more on on our global site global site astrazeneca's global website is intended for people seeking information on astrazeneca's worldwide business. click the 'global site' link for the directory of country sites. resources astrazeneca in the us community support affordability az&you blog quick links contact us media careers medicines social media twitter facebook privacy notice legal notice california supply chains disclosure sitemap copyright ©2016 astrazeneca you are now leaving astrazeneca-us.com you have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. astrazeneca provides this link as a service to website visitors. astrazeneca is not responsible for the privacy policy of any third party websites. we encourage you to read the privacy policy of every website you visit. click ‘cancel’ to return to astrazeneca’s site or ‘continue’ to proceed. cancel continue ? important notice for users you are about to access astrazeneca historic archive material. any reference in these archives to astrazeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. please refer to your approved national product label (smpc) for current product information. i have read this warning and will not be using any of the contained product information for clinical purposes. i disagree i agree ? ?


Here you find all texts from your page as Google (googlebot) and others search engines seen it.

Words density analysis:

Numbers of all words: 2778

One word

Two words phrases

Three words phrases

the - 4.82% (134)
and - 2.48% (69)
for - 1.73% (48)
can - 1.58% (44)
astrazeneca - 1.51% (42)
are - 1.37% (38)
with - 1.33% (37)
her - 1.3% (36)
2016 - 1.22% (34)
patient - 1.08% (30)
cancer - 1.01% (28)
our - 0.97% (27)
all - 0.86% (24)
you - 0.83% (23)
one - 0.79% (22)
that - 0.72% (20)
disease - 0.68% (19)
health - 0.65% (18)
care - 0.65% (18)
not - 0.65% (18)
his - 0.65% (18)
use - 0.61% (17)
patients - 0.58% (16)
age - 0.58% (16)
this - 0.58% (16)
diabetes - 0.54% (15)
how - 0.54% (15)
year - 0.5% (14)
site - 0.5% (14)
more - 0.43% (12)
out - 0.43% (12)
new - 0.43% (12)
treatment - 0.43% (12)
life - 0.4% (11)
medicine - 0.4% (11)
from - 0.4% (11)
app - 0.4% (11)
diagnosed - 0.36% (10)
has - 0.36% (10)
will - 0.36% (10)
trial - 0.36% (10)
may - 0.36% (10)
years - 0.36% (10)
most - 0.36% (10)
was - 0.36% (10)
search - 0.36% (10)
lung - 0.32% (9)
media - 0.32% (9)
their - 0.32% (9)
clinical - 0.32% (9)
any - 0.32% (9)
million - 0.29% (8)
other - 0.29% (8)
states - 0.29% (8)
united - 0.29% (8)
science - 0.29% (8)
astrazenecaus - 0.29% (8)
ever - 0.29% (8)
your - 0.29% (8)
medical - 0.29% (8)
type - 0.29% (8)
time - 0.29% (8)
part - 0.25% (7)
help - 0.25% (7)
cause - 0.25% (7)
about - 0.25% (7)
what - 0.25% (7)
manage - 0.25% (7)
america - 0.25% (7)
while - 0.25% (7)
important - 0.25% (7)
support - 0.25% (7)
acc - 0.25% (7)
when - 0.25% (7)
dec - 0.25% (7)
these - 0.25% (7)
lead - 0.25% (7)
continue - 0.22% (6)
career - 0.22% (6)
june - 0.22% (6)
she - 0.22% (6)
meeting - 0.22% (6)
experience - 0.22% (6)
website - 0.22% (6)
line - 0.22% (6)
community - 0.22% (6)
blog - 0.22% (6)
research - 0.22% (6)
link - 0.22% (6)
provide - 0.22% (6)
those - 0.22% (6)
personal - 0.22% (6)
people - 0.22% (6)
product - 0.22% (6)
information - 0.22% (6)
have - 0.22% (6)
get - 0.22% (6)
american - 0.22% (6)
its - 0.22% (6)
living - 0.22% (6)
were - 0.18% (5)
cookie - 0.18% (5)
phase - 0.18% (5)
side - 0.18% (5)
share - 0.18% (5)
call - 0.18% (5)
over - 0.18% (5)
some - 0.18% (5)
results - 0.18% (5)
healthcare - 0.18% (5)
cardiovascular - 0.18% (5)
improve - 0.18% (5)
who - 0.18% (5)
access - 0.18% (5)
meetings - 0.18% (5)
had - 0.18% (5)
than - 0.18% (5)
social - 0.18% (5)
global - 0.18% (5)
careers - 0.18% (5)
month - 0.18% (5)
cancer, - 0.18% (5)
stem - 0.18% (5)
november - 0.18% (5)
long - 0.18% (5)
therapy - 0.18% (5)
breast - 0.18% (5)
respiratory - 0.18% (5)
oic - 0.14% (4)
challenges - 0.14% (4)
online - 0.14% (4)
need - 0.14% (4)
work - 0.14% (4)
way - 0.14% (4)
october - 0.14% (4)
early - 0.14% (4)
data - 0.14% (4)
connect - 0.14% (4)
after - 0.14% (4)
two - 0.14% (4)
real - 0.14% (4)
does - 0.14% (4)
they - 0.14% (4)
begin - 0.14% (4)
we’re - 0.14% (4)
where - 0.14% (4)
leading - 0.14% (4)
today - 0.14% (4)
recent - 0.14% (4)
april - 0.14% (4)
source - 0.14% (4)
read - 0.14% (4)
now - 0.14% (4)
notice - 0.14% (4)
announced - 0.14% (4)
also - 0.14% (4)
them - 0.14% (4)
show - 0.14% (4)
being - 0.14% (4)
life. - 0.14% (4)
subgroup - 0.14% (4)
it’s - 0.14% (4)
chronic - 0.14% (4)
death - 0.14% (4)
@astrazenecaus - 0.14% (4)
december - 0.14% (4)
medicines - 0.14% (4)
just - 0.14% (4)
policy - 0.14% (4)
uses - 0.14% (4)
give - 0.14% (4)
thing - 0.14% (4)
privacy - 0.11% (3)
virus - 0.11% (3)
nearly - 0.11% (3)
– - 0.11% (3)
during - 0.11% (3)
why - 0.11% (3)
want - 0.11% (3)
personalized - 0.11% (3)
recently - 0.11% (3)
best - 0.11% (3)
program - 0.11% (3)
bring - 0.11% (3)
cookies - 0.11% (3)
treatments - 0.11% (3)
learning - 0.11% (3)
shares - 0.11% (3)
should - 0.11% (3)
taking - 0.11% (3)
fit - 0.11% (3)
active - 0.11% (3)
responsible - 0.11% (3)
team - 0.11% (3)
reduce - 0.11% (3)
find - 0.11% (3)
annual - 0.11% (3)
rsv - 0.11% (3)
idea - 0.11% (3)
sustainability - 0.11% (3)
advancing - 0.11% (3)
approach - 0.11% (3)
diversity - 0.11% (3)
heart - 0.11% (3)
mean - 0.11% (3)
every - 0.11% (3)
conversation - 0.11% (3)
managing - 0.11% (3)
dr. - 0.11% (3)
direct - 0.11% (3)
using - 0.11% (3)
first - 0.11% (3)
september - 0.11% (3)
there - 0.11% (3)
americans - 0.11% (3)
opioid - 0.11% (3)
engage - 0.11% (3)
present - 0.11% (3)
center - 0.11% (3)
add - 0.11% (3)
leukemia - 0.11% (3)
vice - 0.11% (3)
acalabrutinib - 0.11% (3)
technology - 0.11% (3)
day, - 0.11% (3)
see - 0.11% (3)
resource - 0.11% (3)
cell - 0.11% (3)
tagrisso - 0.11% (3)
risk - 0.11% (3)
making - 0.11% (3)
interest - 0.11% (3)
progression - 0.11% (3)
years, - 0.11% (3)
months - 0.11% (3)
favorite - 0.11% (3)
retweet - 0.11% (3)
reply - 0.11% (3)
system - 0.11% (3)
story - 0.11% (3)
pass - 0.11% (3)
management - 0.11% (3)
pain - 0.11% (3)
congress - 0.11% (3)
third - 0.11% (3)
advocate - 0.11% (3)
constipation - 0.11% (3)
are. - 0.11% (3)
continues - 0.11% (3)
melissa - 0.11% (3)
take - 0.11% (3)
expected - 0.11% (3)
cost - 0.11% (3)
analysis - 0.11% (3)
asthma - 0.11% (3)
join - 0.11% (3)
scientific - 0.11% (3)
iii - 0.11% (3)
metastatic - 0.11% (3)
study - 0.11% (3)
perspective - 0.11% (3)
walking - 0.11% (3)
common - 0.11% (3)
news - 0.11% (3)
latest - 0.11% (3)
diagnosis - 0.07% (2)
emma - 0.07% (2)
cancer. - 0.07% (2)
significant - 0.07% (2)
sue - 0.07% (2)
came - 0.07% (2)
before - 0.07% (2)
students - 0.07% (2)
genetic - 0.07% (2)
didn’t - 0.07% (2)
today, - 0.07% (2)
could - 0.07% (2)
relative - 0.07% (2)
hereditary - 0.07% (2)
receive - 0.07% (2)
small - 0.07% (2)
skip - 0.07% (2)
hard - 0.07% (2)
astrazeneca's - 0.07% (2)
head - 0.07% (2)
week - 0.07% (2)
own - 0.07% (2)
adults - 0.07% (2)
grow - 0.07% (2)
multi-faceted - 0.07% (2)
discuss - 0.07% (2)
march - 0.07% (2)
information. - 0.07% (2)
click - 0.07% (2)
patient’s - 0.07% (2)
sites. - 0.07% (2)
party - 0.07% (2)
cancel - 0.07% (2)
archive - 0.07% (2)
current - 0.07% (2)
used - 0.07% (2)
refer - 0.07% (2)
national - 0.07% (2)
label - 0.07% (2)
co-suspension - 0.07% (2)
attention - 0.07% (2)
science, - 0.07% (2)
lives - 0.07% (2)
math - 0.07% (2)
metabolic - 0.07% (2)
address - 0.07% (2)
— - 0.07% (2)
long-term - 0.07% (2)
resources - 0.07% (2)
rates - 0.07% (2)
change - 0.07% (2)
ways - 0.07% (2)
saving - 0.07% (2)
ask - 0.07% (2)
but - 0.07% (2)
anyone - 0.07% (2)
purposeful - 0.07% (2)
increase - 0.07% (2)
impact - 0.07% (2)
number - 0.07% (2)
aspect - 0.07% (2)
president, - 0.07% (2)
advocates - 0.07% (2)
right - 0.07% (2)
place - 0.07% (2)
bringing - 0.07% (2)
#sabcs16 - 0.07% (2)
across - 0.07% (2)
possible - 0.07% (2)
disease. - 0.07% (2)
chemotherapy - 0.07% (2)
improved - 0.07% (2)
almost - 0.07% (2)
overall - 0.07% (2)
population - 0.07% (2)
twitter - 0.07% (2)
cures - 0.07% (2)
act. - 0.07% (2)
message - 0.07% (2)
look - 0.07% (2)
(pfs) - 0.07% (2)
forward - 0.07% (2)
connecting - 0.07% (2)
follow - 0.07% (2)
demonstrate - 0.07% (2)
difficult-to-treat - 0.07% (2)
lymphocytic - 0.07% (2)
i/ii - 0.07% (2)
forms - 0.07% (2)
symbicort - 0.07% (2)
function - 0.07% (2)
pediatric - 0.07% (2)
safety - 0.07% (2)
efficacy - 0.07% (2)
consistent - 0.07% (2)
survival - 0.07% (2)
between - 0.07% (2)
beyond - 0.07% (2)
visit. - 0.07% (2)
reading - 0.07% (2)
close - 0.07% (2)
contact - 0.07% (2)
improving - 0.07% (2)
innovation - 0.07% (2)
business - 0.07% (2)
medications - 0.07% (2)
affordability - 0.07% (2)
journey - 0.07% (2)
quick - 0.07% (2)
links - 0.07% (2)
copd, - 0.07% (2)
progression-free - 0.07% (2)
lived - 0.07% (2)
never - 0.07% (2)
thought - 0.07% (2)
edna - 0.07% (2)
announces - 0.07% (2)
falcon - 0.07% (2)
subset - 0.07% (2)
non-visceral - 0.07% (2)
faslodex - 0.07% (2)
1st - 0.07% (2)
pre-specified - 0.07% (2)
positive - 0.07% (2)
effects - 0.07% (2)
micrograms - 0.07% (2)
budesonide - 0.07% (2)
like - 0.07% (2)
illness - 0.07% (2)
appropriate - 0.07% (2)
$75 - 0.07% (2)
award - 0.07% (2)
coronary - 0.07% (2)
association - 0.07% (2)
doctors - 0.07% (2)
kristin - 0.07% (2)
different - 0.07% (2)
going - 0.07% (2)
hopeful - 0.07% (2)
offers - 0.07% (2)
mental - 0.07% (2)
nine - 0.07% (2)
top - 0.07% (2)
ago, - 0.07% (2)
danei - 0.07% (2)
executive - 0.07% (2)
family - 0.07% (2)
then - 0.07% (2)
unexpected - 0.07% (2)
break - 0.07% (2)
called - 0.07% (2)
power - 0.07% (2)
astrazeneca’s - 0.07% (2)
5th - 0.07% (2)
women’s - 0.07% (2)
summit - 0.07% (2)
trial? - 0.07% (2)
start - 0.07% (2)
az&you - 0.07% (2)
means - 0.07% (2)
given - 0.07% (2)
five - 0.07% (2)
live. - 0.07% (2)
back - 0.07% (2)
getting - 0.07% (2)
cancerlinq - 0.07% (2)
discovery - 0.07% (2)
exciting - 0.07% (2)
field - 0.07% (2)
greater - 0.07% (2)
accessible - 0.07% (2)
content - 0.07% (2)
care. - 0.07% (2)
treatment, - 0.07% (2)
each - 0.07% (2)
estimated - 0.07% (2)
exactly - 0.07% (2)
phil - 0.07% (2)
understand - 0.07% (2)
experience. - 0.07% (2)
voice - 0.07% (2)
hosted - 0.07% (2)
season - 0.07% (2)
better - 0.07% (2)
hospitalization - 0.07% (2)
life, - 0.07% (2)
200 - 0.07% (2)
infant - 0.07% (2)
agree - 0.07% (2)
in the - 0.58% (16)
of the - 0.47% (13)
united states - 0.29% (8)
type 2 - 0.25% (7)
diagnosed with - 0.25% (7)
2 diabetes - 0.22% (6)
clinical trial - 0.22% (6)
living with - 0.22% (6)
lung cancer - 0.22% (6)
the united - 0.22% (6)
the most - 0.22% (6)
patients with - 0.22% (6)
november 2016 - 0.18% (5)
social media - 0.18% (5)
at the - 0.18% (5)
one of - 0.18% (5)
june 2016 - 0.18% (5)
to help - 0.18% (5)
and the - 0.14% (4)
may 2016 - 0.14% (4)
global site - 0.14% (4)
medical meetings - 0.14% (4)
a patient - 0.14% (4)
of patient - 0.14% (4)
breast cancer - 0.14% (4)
to the - 0.14% (4)
astrazeneca in - 0.14% (4)
december 2016 - 0.14% (4)
with type - 0.14% (4)
2016 a - 0.14% (4)
october 2016 - 0.14% (4)
is one - 0.14% (4)
september 2016 - 0.11% (3)
results from - 0.11% (3)
your health - 0.11% (3)
2016 making - 0.11% (3)
personal in - 0.11% (3)
astrazeneca is - 0.11% (3)
making medicine - 0.11% (3)
with lung - 0.11% (3)
to manage - 0.11% (3)
on the - 0.11% (3)
will be - 0.11% (3)
for more - 0.11% (3)
cancer treatment - 0.11% (3)
their treatment - 0.11% (3)
medicine personal - 0.11% (3)
age of - 0.11% (3)
cause of - 0.11% (3)
reply retweet - 0.11% (3)
leading cause - 0.11% (3)
on our - 0.11% (3)
to astrazeneca - 0.11% (3)
for the - 0.11% (3)
phase iii - 0.11% (3)
of disease - 0.11% (3)
subgroup analysis - 0.11% (3)
million americans - 0.11% (3)
you are - 0.11% (3)
astrazenecaus @astrazenecaus - 0.11% (3)
dec 08 - 0.11% (3)
in science - 0.07% (2)
no idea - 0.07% (2)
risk of - 0.07% (2)
responsible for - 0.07% (2)
the american - 0.07% (2)
access to - 0.07% (2)
meetings to - 0.07% (2)
the age - 0.07% (2)
privacy policy - 0.07% (2)
provide a - 0.07% (2)
1 september - 0.07% (2)
i never - 0.07% (2)
third party - 0.07% (2)
the privacy - 0.07% (2)
at astrazeneca - 0.07% (2)
of information - 0.07% (2)
not be - 0.07% (2)
you visit. - 0.07% (2)
cost of - 0.07% (2)
policy of - 0.07% (2)
and metabolic - 0.07% (2)
students in - 0.07% (2)
co-suspension technology - 0.07% (2)
for patients - 0.07% (2)
you to - 0.07% (2)
most important - 0.07% (2)
to grow - 0.07% (2)
5 april - 0.07% (2)
may not - 0.07% (2)
cardiovascular disease - 0.07% (2)
a patient’s - 0.07% (2)
and science - 0.07% (2)
forms of - 0.07% (2)
and at - 0.07% (2)
vice president, - 0.07% (2)
beyond the - 0.07% (2)
will take - 0.07% (2)
respiratory health - 0.07% (2)
any of - 0.07% (2)
information on - 0.07% (2)
interest in - 0.07% (2)
with cancer, - 0.07% (2)
contact us - 0.07% (2)
media careers - 0.07% (2)
be diagnosed - 0.07% (2)
new cancer - 0.07% (2)
in respiratory - 0.07% (2)
opioid treatment - 0.07% (2)
skip to - 0.07% (2)
does not - 0.07% (2)
important to - 0.07% (2)
most common - 0.07% (2)
of patients - 0.07% (2)
of acalabrutinib - 0.07% (2)
astrazeneca and - 0.07% (2)
phase i/ii - 0.07% (2)
lymphocytic leukemia - 0.07% (2)
acalabrutinib in - 0.07% (2)
favorite 0 - 0.07% (2)
retweet 0 - 0.07% (2)
to share - 0.07% (2)
0 favorite - 0.07% (2)
the present - 0.07% (2)
shares her - 0.07% (2)
08 astrazenecaus - 0.07% (2)
with the - 0.07% (2)
function in - 0.07% (2)
survival (pfs) - 0.07% (2)
from a - 0.07% (2)
non-visceral disease - 0.07% (2)
falcon trial - 0.07% (2)
astrazeneca united - 0.07% (2)
news from - 0.07% (2)
quick links - 0.07% (2)
information for - 0.07% (2)
astrazeneca medications - 0.07% (2)
health and - 0.07% (2)
to care - 0.07% (2)
us sustainability - 0.07% (2)
states astrazeneca - 0.07% (2)
website you - 0.07% (2)
astrazeneca announces - 0.07% (2)
from the - 0.07% (2)
women’s summit - 0.07% (2)
this website - 0.07% (2)
5th annual - 0.07% (2)
mental illness - 0.07% (2)
that one - 0.07% (2)
to lead - 0.07% (2)
with metastatic - 0.07% (2)
metastatic breast - 0.07% (2)
million research - 0.07% (2)
heart disease - 0.07% (2)
research award - 0.07% (2)
$75 million - 0.07% (2)
what does - 0.07% (2)
clinical trial? - 0.07% (2)
life, and - 0.07% (2)
is the - 0.07% (2)
astrazeneca recently - 0.07% (2)
lung function - 0.07% (2)
lung cancer, - 0.07% (2)
in pediatric - 0.07% (2)
11 november - 0.07% (2)
az&you blog - 0.07% (2)
was diagnosed - 0.07% (2)
cancer and - 0.07% (2)
out of - 0.07% (2)
2016 what - 0.07% (2)
those living - 0.07% (2)
cancer in - 0.07% (2)
american diabetes - 0.07% (2)
dr. phil - 0.07% (2)
the conversation - 0.07% (2)
how the - 0.07% (2)
people with - 0.07% (2)
product label - 0.07% (2)
type 2 diabetes - 0.22% (6)
in the united - 0.22% (6)
the united states - 0.22% (6)
in the us - 0.14% (4)
is one of - 0.14% (4)
with type 2 - 0.14% (4)
astrazeneca in the - 0.11% (3)
2016 making medicine - 0.11% (3)
medicine personal in - 0.11% (3)
leading cause of - 0.11% (3)
dec 08 astrazenecaus - 0.07% (2)
annual women’s summit - 0.07% (2)
the privacy policy - 0.07% (2)
the most common - 0.07% (2)
had no idea - 0.07% (2)
most important aspect - 0.07% (2)
the most important - 0.07% (2)
diagnosed with copd, - 0.07% (2)
astrazeneca recently hosted - 0.07% (2)
cardiovascular and metabolic - 0.07% (2)
of patients with - 0.07% (2)
progression-free survival (pfs) - 0.07% (2)
patients with non-visceral - 0.07% (2)
no idea that - 0.07% (2)
with metastatic breast - 0.07% (2)
of acalabrutinib in - 0.07% (2)
a $75 million - 0.07% (2)
coronary heart disease - 0.07% (2)
a clinical trial? - 0.07% (2)
diagnosed with cancer, - 0.07% (2)
united states astrazeneca - 0.07% (2)
those living with - 0.07% (2)
the type 2 - 0.07% (2)
favorite 0 dec - 0.07% (2)
for more than - 0.07% (2)
08 astrazenecaus @astrazenecaus - 0.07% (2)
11 november 2016 - 0.07% (2)
function in pediatric - 0.07% (2)
results from the - 0.07% (2)
any of the - 0.07% (2)

Here you can find chart of all your popular one, two and three word phrases. Google and others search engines means your page is about words you use frequently.

Copyright © 2015-2016 hupso.pl. All rights reserved. FB | +G | Twitter

Hupso.pl jest serwisem internetowym, w którym jednym kliknieciem możesz szybko i łatwo sprawdź stronę www pod kątem SEO. Oferujemy darmowe pozycjonowanie stron internetowych oraz wycena domen i stron internetowych. Prowadzimy ranking polskich stron internetowych oraz ranking stron alexa.